[1]周子杰,张家豪,姜吉霖,等.miR-586通过SFRP1调控骨肉瘤细胞增殖、迁移、侵袭的机制研究[J].福建医药杂志,2024,46(01):115-119.[doi:10.20148/j.fmj.2024.01.032]
点击复制

miR-586通过SFRP1调控骨肉瘤细胞增殖、迁移、侵袭的机制研究()
分享到：

《福建医药杂志》[ISSN:1002-2600/CN:35-1071/R]

卷:
46
期数:
2024年01期
页码:
115-119
栏目:
基础研究
出版日期:
2024-02-15

文章信息/Info

文章编号:
1002-2600（2024）01-0115-05
作者:
周子杰1; 2; 张家豪2; 姜吉霖1; 2; 李书林2; 3; 付解辉4; 汤发强1; 2; 3
1 福建中医药大学 中西医结合学院，福州350122；2 福建医科大学 省立临床医学院，福州 350001；3 福建省立医院骨一科，福州 350001；4 福建中医药大学 附属康复医院，福州350122
关键词:
骨肉瘤; 微小RNA; 分泌型卷曲相关蛋白1; SFRP1
分类号:
R738
DOI:
10.20148/j.fmj.2024.01.032
文献标志码:
A
摘要:
目的探究miR-586调控人骨肉瘤细胞U2OS的生物学行为的可能机制。方法通过比较骨肉瘤细胞系和人成骨细胞中miR-586的差异表达筛选目标细胞株，干扰miR-586表达后检测其对目标细胞株增殖、迁移、侵袭能力的影响；用双荧光素酶实验、实时荧光定量聚合酶链式反应、Western blot验证miR-586与SFRP1相关性，检测干预miR-586、SFRP1后对目标细胞株迁移、侵袭能力的影响。结果相较于人成骨细胞hFOB1.19，骨肉瘤细胞系中U2OS细胞的miR-586表达量显著增加；调低miR-586后U2OS细胞增殖、侵袭、迁移能力下降，SFRP1的mRNA及蛋白表达增加；过表达miR-586后U2OS细胞增殖、侵袭、迁移能力上升，SFRP1的mRNA及蛋白表达下降；同时调低miR-586、SFRP1后，U2OS细胞侵袭及迁移能力较敲低miR-586组上升。结论在本研究中，miR-586/ SFRP1轴调控骨肉瘤细胞U2OS的增殖与生物学行为，具有作为骨肉瘤的潜在诊断、治疗标志物的可能性。

参考文献/References:

[1] CORTINI M,AVNET S,BALDINI N.Mesenchymal stroma: Role in osteosarcoma progression [J].Cancer Lett,2017,405: 90-99.
[2] ROSEN G,MARCOVE R C,CAPARROS B,et al.Primary osteogenic sarcoma: the rationale for preoperative chemothe-rapy and delayed surgery [J].Cancer,1979,43(6): 2163-2177.
[3] GORLICK R,JANEWAY K,LESSNICK S,et al.Children's Oncology Group's 2013 blueprint for research: bone tumors [J].Pediatr Blood Cancer,2013,60(6): 1009-1015.
[4] HILL M,TRAN N.miRNA interplay: mechanisms and con-sequences in cancer [J].Dis Model Mech,2021,14(4): dmm047662.
[5] SALIMINEJAD K,KHORRAM KHORSHID H R,SOLEYMANI FARD S,et al.An overview of microRNAs: biology,functions,therapeutics,and analysis methods [J].J Cell Physiol,2019,234(5): 5451-5465.
[6] ANDERSEN G B,KNUDSEN A,HAGER H,et al.miRNA profiling identifies deregulated miRNAs associated with osteosarcoma development and time to metastasis in two large cohorts [J].Mol Oncol,2018,12(1): 114-131.
[7] CHANG Y H,HUANG Y L,TSAI H C,et al.Chemokine ligand 2 promotes migration in osteosarcoma by regulating the miR-3659/ MMP-3 Axis [J].Biomedicines,2023,11(10):2768.
[8] ZHENG C,LI R,ZHENG S,et al.The knockdown of lncRNA DLGAP1-AS2 suppresses osteosarcoma progression by inhibiting aerobic glycolysis via the miR-451a/HK2 axis [J].Cancer Sci,2023,114(12):4747-4762.
[9] SAADH M J,RASHED A B,JAMAL A,et al.miR-199a-3p suppresses neuroinflammation by directly targeting MyD88 in a mouse model of bone cancer pain [J].Life Sci,2023,333: 122139.
[10] ZHANG D,LIU X,LI Y,et al.LINC01189-miR-586-ZEB1 feedback loop regulates breast cancer progression through Wnt/beta-catenin signaling pathway [J].Mol Ther Nucleic Acids,2021,25: 455-467.
[11] LIU C,YANG J,ZHU F,et al.Exosomal circ_0001190 regulates the progression of gastric cancer via miR-586/SOSTDC1 axis [J].Biochem Genet,2022,60(6): 1895-1913.
[12] LUO Y,HOU W T,ZENG L,et al.Progress in the study of markers related to glioma prognosis [J].Eur Rev Med Pharmacol Sci,2020,24(14): 7690-7697.
[13] MOHAPATRA P,MADHULIKA S,BEHERA S,et al.Nimbolide-based nanomedicine inhibits breast cancer stem-like cells by epigenetic reprogramming of DNMTs-SFRP1-Wnt/β-catenin signaling axis [J].Mol Ther Nucleic Acids,2023,34: 102031.
[14] BAHARUDIN R,TIENG F Y F,LEE L H,et al.Epigenetics of SFRP1: the dual roles in human cancers[J].Cancers(Basel),2020,12(2): 445.
[15] ATSCHEKZEI F,HENNENLOTTER J,JANISCH S,et al.SFRP1 CpG island methylation locus is associated with renal cell cancer susceptibility and disease recurrence[J].Epigenetics,2012,7(5): 447-457.
[16] HENG L,JIA Z,BAI J,et al.Molecular characterization of metastatic osteosarcoma: differentially expressed genes,transcription factors and microRNAs [J].Mol Med Rep,2017,15(5): 2829-2836.
[17] ALESSANDRINI L,MANCHI M,DE RE V,et al.Proposed molecular and miRNA classification of gastric cancer [J].Int J Mol Sci,2018,19(6): 1683.
[18] SABIT H,CEVIK E,TOMBULOGLU H,et al.Triple negative breast cancer in the era of miRNA [J].Crit Rev Oncol Hematol,2021,157: 103196.
[19] GHAFOURI-FARD S,HONARMAND TAMIZKAR K,HUSSEN B M,et al.MicroRNA signature in liver cancer [J].Pathol Res Pract,2021,219: 153369.
[20] 袁长深,容伟明,卢智贤,等.基于生物信息学构建骨肉瘤miRNA-mRNA的调控网络[J].中国组织工程研究,2021,25(17): 2740-2746.

相似文献/References:

[1]许扬梅 龚福生 刘沁颖 刘施佳 黄丽洁 郑秋红.MiR-194过表达和抑制表达对肝癌细胞株Hep-3b中侧群细胞增殖的影响[J].福建医药杂志,2019,41(06):141.
　XU Yangmei,GONG Fusheng,LIU Qinying,et al.Influence of miR-194 up and down-expression on liver cancer stem cells[J].FUJIAN MEDICAL JOURNAL,2019,41(01):141.
[2]林文韬 王武炼 肖莉莉 张怡元.基于GEO数据库发现骨肉瘤关键基因GMFG及其生物学功能[J].福建医药杂志,2020,42(02):112.
　LIN Wentao,WANG Wulian,XIAO Lili,et al.Identification of the key gene GMFG and its biological function in osteosarcoma based on GEO database[J].FUJIAN MEDICAL JOURNAL,2020,42(01):112.
[3]肖莉莉 刘 晖 贾春锋.基于核酸适配体的微流控芯片的构建及对循环肿瘤细胞筛选性能的测定[J].福建医药杂志,2020,42(02):119.
[4]陈康尧,顾恩毅,蔡碰德,等.H1受体拮抗剂异丙嗪对顺铂治疗骨肉瘤的影响及机制[J].福建医药杂志,2021,43(04):132.
　CHEN Kangyao,GU Enyi,CAI Pengde,et al.Efficacy and mechanism of H1 receptor antagonist promethazine on osteosarcoma treated with cisplatin[J].FUJIAN MEDICAL JOURNAL,2021,43(01):132.
[5]钟志辉,林焱斌,庄 研,等.骨肉瘤组织ACTN4和CD133的表达及其影响因素[J].福建医药杂志,2021,43(05):117.
　ZHONG Zhihui,LIN Yanbin,ZHUANG Yan,et al.Expression and interfering factors of ACTN4 and CD133 in osteosarcoma[J].FUJIAN MEDICAL JOURNAL,2021,43(01):117.
[6]林东泽.shRNA沉默c-myc基因对MG-63骨肉瘤细胞c-myc/PD-L1轴的影响[J].福建医药杂志,2022,44(05):133.

备注/Memo

备注/Memo:
通信作者：汤发强，Email:faqiangtang@163.com
更新日期/Last Update: 2024-02-15